| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 04/29/2026 | ±3.3% | +5.8% | under-priced |
| 02/19/2026 | ±4.3% | +1.8% | over-priced |
| 11/05/2025 | ±2.9% | -6.0% | under-priced |
| 07/30/2025 | ±3.9% | +12.4% | under-priced |
| 04/30/2025 | ±3.0% | +1.1% | over-priced |
| 02/20/2025 | ±3.7% | +2.2% | over-priced |
| 10/30/2024 | ±2.8% | +3.3% | under-priced |
| 07/31/2024 | ±2.8% | -10.6% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $9.83 | $39.6B | $1.2B |
| Q4 FY2025 | — | $32.5B | $-796M |
| Q3 FY2025 | $1.62 | $32.6B | $195M |
| Q2 FY2025 | $4.51 | $32.4B | $545M |
HUM (HUM) reports imminently, with the next report estimated for 10/26/2026. Across the last 8 reports, options priced an average ±3.3% earnings move while the stock actually moved 5.4% on average — the market has been roughly fair on HUM's earnings risk. Fundamentals into the print: EPS down 4.6% year-over-year, revenue up 23.5%. QuantLogix's live 5-factor engine currently reads HUM as a buy at 73/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →